{
    "clinical_study": {
        "@rank": "107505", 
        "arm_group": [
            {
                "arm_group_label": "Part A:  Telmisartan, Chlorthalidone + Telmisartan", 
                "arm_group_type": "Active Comparator", 
                "description": "telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally"
            }, 
            {
                "arm_group_label": "Part B: Chlorthalidone, Chlorthalidone + Telmisartan", 
                "arm_group_type": "Active Comparator", 
                "description": "telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan\n      and chlorthalidone."
        }, 
        "brief_title": "Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subjects\n\n          2. Age(yr)between 20 and 50\n\n          3. Signed written informed consent\n\n        Exclusion Criteria:\n\n          1. Known hypersensitivity to investigator product, thiazide, sulphonamide and other\n             drugs or additive.\n\n          2. History of any siginificant Sickness, Cardiovascular, Respiratory, Renal, Endocrine,\n             Neurological, Psychic, Cancer, Gasstrointestinal, Hematologic.\n\n          3. History of drug and/or alcohol abuse\n\n          4. Over 10 tobaccos a day\n\n          5. Other condition which in the opinion of the investigator preclude enrollment into the\n             study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806363", 
            "org_study_id": "HTECHL12I_1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A:  Telmisartan, Chlorthalidone + Telmisartan", 
                    "Part B: Chlorthalidone, Chlorthalidone + Telmisartan"
                ], 
                "intervention_name": "Telmisartan 80mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A:  Telmisartan, Chlorthalidone + Telmisartan", 
                    "Part B: Chlorthalidone, Chlorthalidone + Telmisartan"
                ], 
                "intervention_name": "Chlorthalidone 25mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorthalidone", 
                "Telmisartan", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Safety", 
            "Male"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeongsangbuk-do", 
                    "zip": "700-721"
                }, 
                "name": "Kyungpook national university hospital Clionical center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.", 
        "overall_official": {
            "affiliation": "KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, CLINICAL TRIAL CENTER", 
            "last_name": "Young Ran Yoon, Associate Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Part A : AUC, Cmax of Telmisartan", 
                "safety_issue": "Yes", 
                "time_frame": "Over a 24-hour sampling period"
            }, 
            {
                "measure": "Part B : AUC, Cmax of Chlorthalidone", 
                "safety_issue": "Yes", 
                "time_frame": "Over a 24-hour sampling period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part A : Cmin, tmax, CL/F of Telmisartan", 
                "safety_issue": "No", 
                "time_frame": "Over a 24-hour sampling period"
            }, 
            {
                "measure": "Part B : Cmin, tmax, CL/F of Chlorthalidone", 
                "safety_issue": "No", 
                "time_frame": "Over a 24-hour sampling period"
            }
        ], 
        "source": "HanAll BioPharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HanAll BioPharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}